 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...90919293949596979899100...123124» |
- || lenvatinib / Generic mfg.
Never full dose !!! Liberal dose reduction of Lenvima (Twitter) - Jan 28, 2021
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors (clinicaltrials.gov) - Jan 28, 2021
P2, N=30, Suspended, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||| Kaitanni (cadonilimab) / Akesobio
New P2 trial, Combination therapy, Metastases: AK104-209: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 27, 2021
P2, N=75, Recruiting, Sponsor: Akeso
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Pembrolizumab And Lenvatinib In Leptomeningeal Metastases (clinicaltrials.gov) - Jan 27, 2021
P2, N=19, Not yet recruiting, Sponsor: Massachusetts General Hospital
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical: A4. Ive been surprised at how hard it can be to tolerate lenvatinib and pembrolizumab. I wonder if there is a particular clinical profile of people with #endometrialcancer that predicts higher likelihood they can take it? #GynOncChat (Twitter) - Jan 27, 2021
- | Journal, Cancer stem cells: CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma. (Pubmed Central) - Jan 27, 2021
Collectively, CD73 plays a critical role in sustaining CSCs traits by upregulating SOX9 expression and enhancing its protein stability. Targeting CD73 might be a promising strategy to eradicate CSCs and reverse Lenvatinib resistance in HCC.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal, HEOR: Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia. (Pubmed Central) - Jan 27, 2021
Targeting CD73 might be a promising strategy to eradicate CSCs and reverse Lenvatinib resistance in HCC. Our study found that, at current prices, lenvatinib is a cost-effective treatment option compared with sorafenib for the first-line treatment of patients with advanced HCC.
- ||| Nexavar (sorafenib) / Bayer, Amgen
They are likely all similar . Lenvatinib and sorafenib are less preferred since they have not been vigorously tested beyond 1L and/or post VEGFi. Cabo inhibits AXL and Met theoretically MO resistance to VEGFi. IO post IO needs more data. (Twitter) - Jan 26, 2021
- || Nexavar (sorafenib) / Bayer, Amgen
To be honest, I do not like sorafenib. But in clinic I used it in this scenario over lenvatinib just because the chance of P2P and treatment delays is less. (Twitter) - Jan 26, 2021
- ||| Nexavar (sorafenib) / Bayer, Amgen
Clinical: Definitely a TKI. Would favor lenvatinib due to higher ORR/PFS compared w/ sorafenib. Also, some promising early data on the combo of lenva/IO suggest that this drug might be a good choice in IO-treated patients. (Twitter) - Jan 26, 2021
- | lenvatinib / Generic mfg.
Biomarker, Journal: Lenvatinib Inhibits AKT/NF-κB Signaling and Induces Apoptosis Through Extrinsic/Intrinsic Pathways in Non-small Cell Lung Cancer. (Pubmed Central) - Jan 26, 2021
Our study found that, at current prices, lenvatinib is a cost-effective treatment option compared with sorafenib for the first-line treatment of patients with advanced HCC. Altogether, lenvatinib induced extrinsic/intrinsic apoptosis and suppressed migration/invasion ability of NSCLC cells that was associated with AKT/NF-κB signaling inactivation.
- || Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, Review, Journal: Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review. (Pubmed Central) - Jan 23, 2021
Due to frailty and comorbidities associated to chronic hemodialysis enhanced vigilance for these therapies within this specific population is recommended. Dedicated prospective clinical trials would definitely help to obtain data with a higher level of evidence.
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, Retrospective data, Review, Journal: Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis. (Pubmed Central) - Jan 23, 2021
Dedicated prospective clinical trials would definitely help to obtain data with a higher level of evidence. VEGR-TKIs, particularly Sunitinib and Regorafenib appear to be associated with increased risk of bleeding incidence.
- | Stivarga (regorafenib) / Bayer, Nexavar (sorafenib) / Bayer, Amgen
Journal: Development of a thrombus in the superior mesenteric artery associated with sequential therapy with tyrosine kinase inhibitors for hepatocellular carcinoma. (Pubmed Central) - Jan 23, 2021
The incidence of ATE is rare in TKI treatment; however, long-term or sequential TKI therapy may increase the frequency of ATE. Further study is needed.
- | lenvatinib / Generic mfg.
Journal: A report of a new late toxic effect of lenvatinib. (Pubmed Central) - Jan 23, 2021
Further study is needed. No abstract available
- | Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Retrospective data, Journal: Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials. (Pubmed Central) - Jan 23, 2021
In addition, the risk of developing high-grade proteinuria events was significant for patients with hepatocellular carcinoma (HCC) and renal-cell carcinoma (RCC), but not for patients with colorectal cancer (CRC) and thyroid cancer (TC). Treatment with newly approved VEGFR-TKIs significantly increases the risk of developing proteinuria events in cancer patients, especially for patients treated with lenvatinib.
- || lenvatinib / Generic mfg.
Clinical, Journal: Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. (Pubmed Central) - Jan 22, 2021
In this study, we show that AT may improve prognosis in patients with intermediate-stage HCC. Moreover, alternating LEN and trans-arterial therapy may be recommended for patients below 70 years of age with ALBI grade 1.
- || lenvatinib / Generic mfg.
Clinical, Journal: F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib. (Pubmed Central) - Jan 22, 2021
Moreover, alternating LEN and trans-arterial therapy may be recommended for patients below 70 years of age with ALBI grade 1. Tumor response assessment by F-FDG-PET outperforms morphological response assessment by CT in patients with advanced radioiodine refractory DTC treated with Lenvatinib, which seems to be correlated with clinical outcomes.
- || lenvatinib / Generic mfg.
Clinical, Journal: A Case of Long-Term Survival of Anaplastic Transformation of Thyroid Cancer in Lymph Node Metastasis Due to Radiation Therapy and Lenvatinib (Pubmed Central) - Jan 22, 2021
She survived for 3 years while continuing lenvatinib. We reported long-term survival due to radiation therapy and lenvatinib of anaplastic transformation of thyroid cancer in lymph node metastasis due to radiation therapy and lenvatinib.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Combined Modality Therapy for Giant Hepatocellular Carcinoma and Multiple Lung Metastases-A Case Study (Pubmed Central) - Jan 22, 2021
However, these drugs were not effective in this case, whereas arterial injection chemotherapy showed satisfactory therapeutic effect on the recurrences in the liver. Although there was a complication of duodenal ulcer, this case report highlights that combined modality therapy including arterial injection chemotherapy is successful in treating HCC.
- | Caprelsa (vandetanib) / Sanofi, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
Trial termination, Metastases: Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer (clinicaltrials.gov) - Jan 22, 2021
P2, N=6, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Although there was a complication of duodenal ulcer, this case report highlights that combined modality therapy including arterial injection chemotherapy is successful in treating HCC. Active, not recruiting --> Terminated; Lack of efficacy
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial completion date: A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 22, 2021
P=N/A, N=713, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Terminated; Lack of efficacy Active, not recruiting --> Completed | Trial completion date: May 2021 --> Feb 2020
- || Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal: Immunotherapy for advanced hepatocellular carcinoma, where are we? (Pubmed Central) - Jan 21, 2021
Other immunotherapy, such as chimeric antigen receptor T (CAR-T) cell therapy has achieved an evolutional success in hematologic malignancies, and has extended its use in deadly solid tumors, such as HCC. Although there exist various barriers, novel approaches are developed to move potential adoptive T cell therapy strategies, including cytokine-induced killer (CIK) cells, tumor-infiltrating lymphocytes (TIL), T cell receptor (TCR) T cells, CAR-T cells, to clinical application.
- |||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial, Metastases: LEAP-006 China Extension: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study (clinicaltrials.gov) - Jan 19, 2021
P3, N=200, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-na (clinicaltrials.gov) - Jan 19, 2021
P3, N=620, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Although there exist various barriers, novel approaches are developed to move potential adoptive T cell therapy strategies, including cytokine-induced killer (CIK) cells, tumor-infiltrating lymphocytes (TIL), T cell receptor (TCR) T cells, CAR-T cells, to clinical application. Recruiting --> Active, not recruiting
- ||| Clinical: Remarkable result. Love it. Was there any vascular invasion at presentation? Single y90 treatment or required multiple? Looks like maybe 9-10cm HCC? Based on comments it sounds like patient was not even considered for Y90 until intolerance to lenvima? How come... (Twitter) - Jan 17, 2021
- ||| lenvatinib / Generic mfg.
Clinical: Clearly, ORR not be the best way to select TKIs for future RCTs. More G2 in placebo arm, doubt it explains lack of benefit. Would like to see RCT-III of lenvatinib based on TALENT (@Ja_Capdevila - will that happen?). Plz, plz enroll on Alliance CABINET https://t.co/ynZxaCnQoF (Twitter) - Jan 17, 2021
- ||||| Opdivo (nivolumab) / Ono Pharma, BMS, Nexavar (sorafenib) / Bayer, Amgen
Clinical: @RenoHemonc BMS actually has an ongoing trial IPI/NIVO 🆚 SOC 1st line (Lenvatinib or Sorafenib). Granted the trial was designed pre-ATEZO/BEV era & the trial is global; not all places will have ATEZO/BEV; but hard to justify a 1st line trial for HCC without the option. #GI21 💭 (Twitter) - Jan 17, 2021
- ||| Clinical: Julius...really the systemic therapy and Y90 combo did it...luckily patient was referred to us due to severed SE to Lenvatinib. He doesn't want to go back to it now though 😀 (Twitter) - Jan 17, 2021
- letrozole / Generic mfg., lenvatinib / Generic mfg.
[VIRTUAL] Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) () - Jan 17, 2021 - Abstract #YIR2021YIR_83;
- |||| Keytruda (pembrolizumab) / Merck (MSD)
LEAP-005 with interesting activity of pembrolizumab and lenvatinib in MSS mCRC. Excited to see what confirmatory studies show. (Twitter) - Jan 15, 2021
- || Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma. (Pubmed Central) - Jan 15, 2021
Indeed, the first phase-3 trial, combining atezolizumab with bevacizumab, has dramatically changed the outcome of patients. Data from several other types of combinations assessed in phase-3 trials are pending, and if positive, will drastically arm the physicians to efficiently treat the patients, and disrupt the current algorithm of hepatocellular carcinoma treatment.
- || Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. (Pubmed Central) - Jan 15, 2021
A recent phase III trial (IMbrave150) showed that combination immunotherapy with atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency already approved this combination therapy, and worldwide approval is expected soon. This review describes the recent advances in systemic therapy and the use of tyrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib, and cabozantinib), monoclonal antibodies (ramucirumab and bevacizumab), and immune checkpoint inhibitors (nivolumab, pembrolizumab, and atezolizumab) in elderly patients and the similarity of their efficacy and safety profiles to those in the general population.
- | lenvatinib / Generic mfg.
Journal: Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma. (Pubmed Central) - Jan 15, 2021
Oncological aggressiveness of HCC estimated by CT enhancement pattern was predictive of PPS after progression during lenvatinib. Successful subsequent treatment with lenvatinib-TACE sequential therapy may offer survival benefit regardless of CT enhancement pattern of HCC.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
Trial completion date, Trial primary completion date, Metastases: Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer (clinicaltrials.gov) - Jan 15, 2021
P=N/A, N=23, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Successful subsequent treatment with lenvatinib-TACE sequential therapy may offer survival benefit regardless of CT enhancement pattern of HCC. Trial completion date: Nov 2020 --> Nov 2021 | Trial primary completion date: Nov 2020 --> Nov 2021
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: PECATI: Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (clinicaltrials.gov) - Jan 14, 2021
P2, N=43, Not yet recruiting, Sponsor: MedSIR
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 13, 2021
P=N/A, N=30, Recruiting, Sponsor: RenJi Hospital
Trial completion date: Nov 2020 --> Nov 2021 | Trial primary completion date: Nov 2020 --> Nov 2021 Not yet recruiting --> Recruiting
- || lenvatinib / Generic mfg.
Clinical, Journal: Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study. (Pubmed Central) - Jan 13, 2021
The CONUT score was the most important prognostic variable, rather than albumin-bilirubin grade and BCLC stage, in patients with HCC treated with LEN. Accordingly, immuno-nutritional status may be an important factor in the management of patients with HCC treated with LEN.
- | Avastin (bevacizumab) / Roche
Journal: Enhancement of Soft Tissue Sarcoma Response to Gemcitabine through Timed Administration of a Short-Acting Anti-Angiogenic Agent. (Pubmed Central) - Jan 13, 2021
Accordingly, immuno-nutritional status may be an important factor in the management of patients with HCC treated with LEN. We posit that a single delivery of a short-acting anti-angiogenic agent at 1h preceding each dose of gemcitabine and other chemotherapies may be more efficacious for repeated sensitization of the ASMase pathway in multi-cycle chemotherapy regimens than current treatment strategies.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Ibrutinib potentiates anti-hepatocarcinogenic efficacy of sorafenib by targeting EGFR in tumor cells and BTK in immune cells in the stroma. (Pubmed Central) - Jan 13, 2021
Although treatment with sorafenib or lenvatinib is the standard of care in patients with advanced-stage HCC, the survival benefit from sorafenib is limited due to low response rate and drug resistance...Moreover, ibrutinib showed synergy with sorafenib or regorafenib, a sorafenib congener, by inducing apoptosis of HCC cells...Importantly, we found that the BTK+ immune cells were also enriched in the tumor microenvironment in a subset of primary human HCCs. Collectively, our findings implicate BTK signaling in hepatocarcinogenesis and support clinical trials of the sorafenib-ibrutinib combination for this deadly disease.
- || lenvatinib / Generic mfg.
Biomarker, Clinical, Journal: Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. (Pubmed Central) - Jan 12, 2021
The NOS3 rs2070744 genotypes did not influence the clinical response. However, the SNP combination pattern of the NOS3 rs2070744 and FGFR4 rs351855 genotypes may be helpful as treatment effect predictors and prognostic factors for HCC patients treated with lenvatinib.
- ||| Avastin (bevacizumab) / Roche
Clinical, Clinical guideline, Journal: Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. (Pubmed Central) - Jan 12, 2021
Systemic therapy, including the atezolizumab/bevacizumab combination and tyrosine kinase inhibitors (TKI) like sorafenib and lenvatinib, is used for advanced stages. Supportive care is advised for terminal stage HCC.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: KEYNOTE-B61: Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (clinicaltrials.gov) - Jan 10, 2021
P2, N=152, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- || lenvatinib / Generic mfg.
Review, Journal: Lenvatinib for Hepatocellular Carcinoma: A Literature Review. (Pubmed Central) - Jan 10, 2021
Upfront systemic therapy may be better for the BCLC intermediate stage HCC patients with a high tumor burden, while selective TACE will be recommended for obtaining a curative response in patients with a low tumor burden. This article reviews the therapeutic response, management of adverse events, post-progression treatment after Lenvatinib, and treatment strategy for BCLC intermediate stage HCC.
- ||| lenvatinib / Generic mfg.
Clinical, Journal, Adverse events: Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis. (Pubmed Central) - Jan 9, 2021
Conversely, overall survival was longer among patients with DTC and hand-foot syndrome (HFS). Therefore, the present study illustrated that although lenvatinib therapy can result in severe AEs requiring dose reduction or treatment discontinuation, the HFS appearance portends a good prognosis in patients treated with lenvatinib.
- || Clinical, Journal: Surgical indications and clinical management of benign and malignant follicular thyroid tumors: An algorithmic-based approach. (Pubmed Central) - Jan 9, 2021
The results of the present study suggested that the prognosis of WIFTC was the worst among patients with FTC and distant metastasis, and that total thyroidectomy surgery and radioactive iodine treatment are essential. Additionally, if the disease progresses, prompt inclusion of tyrosine kinase inhibitor therapy is necessary.
- |||||| Keytruda (pembrolizumab) / Merck (MSD), Sutent (sunitinib) / Pfizer
Clinical: ASCO GU renal ca highlights. 1) The CLEAR trail. Lenvatinib with pembro or everolumus vs sunitinib. We know the study is positive, but is the pembro arm as good as other combos . 2) SWOG1500: a randomised trial in papillary renal cancer - is cabo or savo better than sunitinib. (Twitter) - Jan 9, 2021
- belzutifan (MK-6482) / Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Phase III study evaluating efficacy and safety of MK-6482 + lenvatinib versus cabozantinib for second- or third-line therapy in patients with advanced renal cell carcinoma (RCC) who progressed after prior anti-PD-1/L1 therapy. () - Jan 8, 2021 - Abstract #ASCOGU2021ASCO_GU_726;
P3
Secondary end points are objective response rate and duration of response per RECIST v1.1 as assessed by BICR, and safety. Safety and tolerability will be evaluated using a tiered approach.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21). () - Jan 8, 2021 - Abstract #ASCOGU2021ASCO_GU_498;
This study showed a longer post-progression OS in pts continuing Cabo beyond PD than in those who switched to another therapy. With the limitations of a retrospective analysis, this is the first evidence suggesting that maintaining Cabo beyond PD is an effective strategy in pts with mRCC.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The BEYOND study (Meet-Uro 19). () - Jan 8, 2021 - Abstract #ASCOGU2021ASCO_GU_497;
However, although sorafenib seems to demonstrate better results, we cannot indicate which is the drug of choice, as no significant advantage was shown in terms of OS or PFS from the comparison between sorafenib and everolimus. The limitations of this study are given by the size of the sample examined and its retrospective nature.